
Producer @CNBCFastMoney / engagements ≠ endorsements
New York, NY
Joined January 2022
- Tweets139
- Following507
- Followers166
- Likes3.3K
An honor to have @DavidSolomon join us on such an important day for our country
Goldman Sachs CEO David Solomon reflects on 9/11 as NYC marks the 25th anniversary of the attacks
@DavidSolomon @GoldmanSachs
cnb.cx/4h3aR8O
1
256
Anna Gleason retweeted
Goldman Sachs CEO David Solomon reflects on 9/11 as NYC marks the 25th anniversary of the attacks
@DavidSolomon @GoldmanSachs
cnb.cx/4h3aR8O
Anna Gleason retweeted
Job growth is one of @RyanSerhant's top metrics when it comes to picking a city to buy a property in today. @Serhant_
cnbc.com/video/2026/07/27/se…
Worth a read!
Inside the Chinese fraud rings stealing billions from banks and retailers cnbc.com/2026/07/17/tap-pay-…
Anna Gleason retweeted
"Positive messaging on Iran would go a long way," says @shehzadhqazi of @ChinaBeigeBook on potential outcomes from the Trump-Xi meeting.
cnbc.com/video/2026/05/13/ch…
Anna Gleason retweeted
Do you have an elderly or disabled neighbor in NYC?
Be a good neighbor and let them know about the free air conditioner program.
If they earn $3473 or less a month, NYC will cover the costs of an A/C. Remember…last summer we had 95 degree weather. Look out for them
Anna Gleason retweeted
"We have potentially the best in class profile based on efficacy, safety, manufacturing and one of the futures I think for this field: combinability," says @StructureTx CEO Ray Stevens.
He discusses $GPCR's portfolio as the company nears $6B in value.
cnbc.com/video/2026/01/15/st…
Anna Gleason retweeted
Novo Nordisk's Wegovy pill is launching direct-to-consumer with @ro
CEO @ZReitano breaks down what the launch means for patients, his company's partnership with $NVO, and more cnb.cx/4aSUKJP
Anna Gleason retweeted
Defense innovation and space are emerging areas in the private side, says @alumniventures's Laura Rippy.
The VC investor also talks the rise of AI investing and the 2026 companies to watch.
cnbc.com/video/2025/12/30/we…
Anna Gleason retweeted
What does #Bitcoin's breakdown mean for digital asset treasury companies like $MSTR and beyond?
@PanteraCapital's @Cosmo_Jiang digs into the numbers and the health of the crypto system cnb.cx/4ao8R9q
Anna Gleason retweeted
20% upside for tech in 2026?
That's Wedbush's @DivesTech's bull case! His views on the AI trade, $NVDA's latest bet, the market's biggest risks, and more cnb.cx/4pHUG3p
Anna Gleason retweeted
Oracle and CoreWeave represent the bad behavior in the AI buildout, warns @gilluria of @DADavidsonCo
He says $MSFT $AMZN $GOOGL are better positioned due to their tremendous cash flow.
$ORCL $CRWV
cnbc.com/video/2025/11/12/or…
Anna Gleason retweeted
Who's the biggest winner in the biotech space?
Leerink's David Risinger just upgraded $LLY to outperform and stuck a $1,104 price target on the GLP-1 giant. He lays out why he's getting bullish on M&A prospects and beyond cnb.cx/3LWDc4I
Anna Gleason retweeted
A biotech breakout filled with superlatives!
$IBB having its best day since may, $LLY hitting a fresh record high, and more...
@TimSeymour, @GuyAdami, @TimSeymour, and Dan Nathan break down the action cnb.cx/4oIPnRy
Anna Gleason retweeted
Insmed is nearly on pace with Palantir for gains this year - nearly tripling!
What are the next catalysts for the high-flyer in the gene therapy space and beyond? @Insmed CEO Will Lewis breaks it down cnb.cx/49xvGHh
Anna Gleason retweeted
Biopharma companies are betting big on drugs that treat MASH, a serious liver disease linked to obesity and metabolic issues.
@MadrigalPharma's MASH drug was the first to clear the FDA. $MDGL CEO Bill Sibold lays out the outlook for the space:
cnbc.com/video/2025/10/16/ma…
Anna Gleason retweeted
$KVUE recovering some of Monday's losses after hours after the Trump administration linked its Tylenol product to autism
Dr. @ashishkjha says health professionals will continue to push back on that claim, and breaks down what's next for the industry cnb.cx/3Kz6sxO
Anna Gleason retweeted
A new disruptor in the weight loss space?
@SignosHealth nabbing FDA approval for the first-ever glucose monitoring system for weight management. CEO @sharamfm discusses the use case for wearable health tech amid sky-high demand for GLP-1 drugs:
cnbc.com/video/2025/09/10/si…
Anna Gleason retweeted
"If you don't have innovation, you can't raise price..."
Needham's Laura Martin breaks down what she calls $AAPL's disappointing iPhone 17 reveal, pricing problems, and lackluster AI capabilities for new hardware cnb.cx/3JX46Zq





